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Novelty and Impact 
This study presents the serological analysis of an association of Streptococcus gallolyticus 
sub-species gallolyticus (SGG) with CRC in a prospective setting with samples from the 
large European Prospective Investigation into Nutrition and Cancer (EPIC) study. We 
found for the first time an association of antibody responses to SGG proteins with CRC risk 
already detectable with pre-diagnostic samples. The presented results support that SGG 
serology might provide a specific marker for risk of developing CRC. 
  3 
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Abstract 4 
The gut microbiome is increasingly implicated in colorectal cancer (CRC) development. A 5 
subgroup of patients diagnosed with CRC show high antibody responses to Streptococcus 6 
gallolyticus subspecies gallolyticus (SGG). However, it is unclear whether the association is 7 
also present pre-diagnostically. We assessed the association of antibody responses to SGG 8 
proteins in pre-diagnostic serum samples with CRC risk in a case-control study nested within 9 
a prospective cohort. 10 
Pre-diagnostic serum samples from 485 first incident CRC cases (mean time between blood 11 
draw and diagnosis 3.4 years) and 485 matched controls in the European Prospective 12 
Investigation into Nutrition and Cancer (EPIC) study were analyzed for antibody responses to 13 
eleven SGG proteins using multiplex serology. Odds ratios (OR) and 95 % confidence 14 
intervals (CI) were estimated using multivariable conditional logistic regression models.  15 
Antibody positivity for any of the eleven SGG proteins was significantly associated with CRC 16 
risk with 56% positive controls compared to 63% positive cases (OR: 1.36, 95% CI: 1.04-17 
1.77). Positivity for two or more proteins of a previously identified SGG 6-marker panel with 18 
greater CRC-specificity was also observed among 9% of controls compared to 17% of CRC 19 
cases, corresponding to a significantly increased CRC risk (OR: 2.17, 95% CI: 1.44-3.27).  20 
In this prospective nested case-control study we observed a positive association between 21 
antibody responses to SGG and CRC development in serum samples taken pre-diagnostically. 22 
Further work is required to establish the possibly etiological significance of these 23 
observations and whether SGG serology may be applicable for CRC risk stratification.  24 
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Introduction 25 
Colorectal cancer (CRC) is among the most frequently diagnosed cancers worldwide with an 26 
incidence of 746,000 new cases among men and 614,000 new cases among women in 20121. 27 
Inflammation is thought to be among the major etiological risk factors for the development of 28 
CRC, and is a possible mechanism through which bacterial infections might contribute to 29 
carcinogenesis2. Changes in the local intestinal tissue can compromise the colonic barrier 30 
integrity resulting in a “leaky gut”3. Certain bacteria may opportunistically infect the intestinal 31 
tissue and potentially induce an immune response, although they usually act as commensals4. 32 
An interesting candidate in this respect might be the intestinal commensal Streptococcus 33 
gallolyticus subspecies gallolyticus (SGG), formerly known as Streptococcus bovis biotype I. 34 
In the 1970’s it was found that infective endocarditis caused by bacteria belonging to the S. 35 
bovis complex5-7, and later more specifically by the subspecies SGG8, co-occurred with the 36 
presence of colorectal adenoma. A systematic review of CRC case series by Boleij et al. in 37 
2011 showed that 60% of S. bovis-infected individuals in the reviewed studies had a 38 
concomitant colorectal adenoma/carcinoma and that SGG-infection was specifically 39 
responsible for this association compared to other S. bovis subtypes9. It is hypothesized that 40 
intestinal lesions are the entry port for the commensal SGG to the blood stream enabling the 41 
bacterium to turn pathogenic and cause bacteremia or endocarditis10. Antibodies against the 42 
infecting SGG may serve as markers for the presence of colorectal neoplasia. A significant 43 
association between SGG antibody response and presence of CRC has been observed in 44 
several studies, but to date these have been exclusively case-control designs with prevalent 45 
CRC cases11-14.  46 
We previously applied multiplex serology, a fluorescent bead-based high-throughput 47 
technology allowing serological typing of several antigens in one reaction15, to analyze 48 
antibody responses to eleven SGG proteins in a German CRC case-control study we showed 49 
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that positivity to two or more proteins of a SGG 6-marker panel (Gallo0272, Gallo0748, 50 
Gallo1675, Gallo2018, Gallo2178 and Gallo2179) was associated with a 1.8-fold (95% CI: 51 
1.07-3.06) increased risk for CRC (n=318) compared to controls (n=228)16. The 6-marker 52 
panel demonstrated a higher specificity for CRC risk compared to positivity towards any one 53 
of the eleven SGG proteins included in the multiplex serology panel. 16. These previous 54 
findings were based on traditional case-control designs where blood samples were obtained 55 
post-diagnosis. It is currently unknown whether any antibody responses to SGG are associated 56 
with CRC development at various time points prior to diagnosis, i.e. whether SGG infection is 57 
merely a consequence of the disease or is in some way involved in CRC etiology17.  58 
In the current study, we evaluated whether antibody responses to SGG proteins, as measured 59 
by multiplex serology, in pre-diagnostic serum samples were associated with the risk of CRC, 60 
using serum samples of a case-control subset (485 cases and 485 matched controls) of 61 
participants of the European Prospective Investigation into Cancer and Nutrition (EPIC) 62 
study.  63 
Methods 64 
Study population, case ascertainment and control selection 65 
EPIC is a multinational cohort to investigate the relation between diet, lifestyle and 66 
environmental factors with cancer incidence. A detailed description of study design has been 67 
published elsewhere18. Briefly, 521,468 participants, aged 35 to 70 years, were enrolled from 68 
10 different European countries (Denmark, France, Greece, Germany, Italy, Netherlands, 69 
Norway, Spain, Sweden, United Kingdom) between 1992 and 2000.  70 
Dietary and lifestyle data as well as biological samples, including serum, were collected at 71 
enrollment. The blood collection and processing protocols were standardized across the study 72 
centers and blood processing and separation was conducted prior to freezing. Serum samples 73 
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were stored at the International agency for research on cancer (IARC, Lyon, France) at -74 
196°C. For multiplex serology analyses, serum samples were shipped on dry ice to the 75 
German Cancer Research Center, Heidelberg. 76 
The nested CRC case-control study analyzed here included pre-diagnostic serum samples 77 
from 492 incident CRC cases (primary tumors, C18-C20 as by the 10th Revision of the 78 
International Statistical Classification of Diseases, Injury and Causes of Death) and 492 79 
matched controls. Controls were selected by incidence density sampling from all cohort 80 
members alive and free of cancer at the time of matching. Cases and controls were matched 81 
1:1 by age at blood collection (±6 month to ±2 years), sex, study center, time of the day at 82 
blood collection (±2 to 4 hours interval), fasting status at blood collection (<3/3-6 hours); 83 
among women by menopausal status, and among premenopausal women, by phase of 84 
menstrual cycle and hormone replacement therapy use at time of blood collection. After 85 
exclusion of 7 case-control pairs due to technical errors during detection, a total of 485 first 86 
incident CRC cases (colon n=432, rectum n=53) were identified that had a mean time 87 
between blood draw and diagnosis of 3.4 years (range 0.4 to 8.5 years) 88 
SGG multiplex serology 89 
Serum samples were analyzed for antibody responses against SGG in a final sample dilution 90 
of 1:1000 using multiplex serology. The method is described in detail elsewhere15, 16. Briefly, 91 
eleven SGG antigens (strain UCN34, Table 1) were bacterially expressed as recombinant 92 
GST-X-tag fusion proteins and each antigen was affinity-purified on a different bead set 93 
marked with a distinct internal fluorescent color (SeroMap, Luminex Corp., Austin, TX, 94 
USA). These differently loaded bead sets were mixed to form a suspension antigen array for 95 
serum presentation. A Luminex xMAP (Luminex Corp., Austin, TX, USA) analyzer 96 
identified the bead set and simultaneously quantified bound serum IgA, IgM and IgG 97 
antibodies by a reporter fluorescent conjugate, Streptavidin-R-Phycoerythrin. The level of 98 
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antibody response was given as median fluorescence intensity (MFI) on at least 100 beads per 99 
set. Net MFI values were generated by subtraction of bead-background and GST-tag 100 
background MFI values.  101 
Due to lack of an appropriate serological gold standard for comparison with our assay, the 102 
cut-off definition for SGG antibody positivity was arbitrarily defined, as described 103 
elsewhere16. The distribution of antibody responses (MFI) to all eleven SGG proteins among 104 
controls was skewed towards low MFI, especially when compared to the outer membrane 105 
protein (OMP) of Helicobacter pylori (H. pylori), analyzed in the same experimental setting 106 
(Fig 1): the upper quartile of antibody responses does not exceed 100 MFI for any of the SGG 107 
antigens, whereas this antibody level was exceeded by 50% of the control sera to H. pylori 108 
OMP. Among controls, we compared the frequency of individuals with the highest antibody 109 
responses (upper 10th percentile) to each protein with the frequency of individuals exceeding 110 
the same level of antibody response among cases. The technical minimum cut-off was 30 MFI 111 
(Table 1). Overall SGG positivity was defined as samples giving a high response to any of the 112 
eleven SGG proteins to allow for individual immune responses and infection with different 113 
strains. In a previous case-control study, we showed that refining the algorithm for overall 114 
SGG positivity to two or more proteins in a 6-marker panel (Gallo0272, Gallo0748, 115 
Gallo1675, Gallo2018, Gallo2178, Gallo2179) strengthened the association with CRC16. This 116 
algorithm was also applied here as a second definition for SGG positivity. 117 
Statistical analyses 118 
Risk factors for SGG positivity among controls were analyzed using Chi-squared-tests. We 119 
estimated the association of incident CRC with antibody responses to individual SGG 120 
proteins, positivity to any of the eleven SGG proteins, or 2 or more proteins of the 6-marker 121 
panel16 using conditional logistic regression models to compute odds ratios (OR) and 95% 122 
confidence intervals (95% CI). A p-value below 0.05 was considered statistically significant. 123 
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Statistical models were first run conditioned on the matching factors, and subsequently with 124 
multivariable adjustment for the following variables: level of education attainment, BMI, 125 
smoking status and level of alcohol consumption [g/day] at baseline assessment. Missing 126 
observations in these variables were included in the model as individual category to save 127 
statistical power. The resulting risk estimates did not substantially differ from those calculated 128 
without further adjustment (supplementary table S1). Sensitivity analyses were carried out 129 
excluding cases diagnosed within two years after blood draw to assess the potential for 130 
reverse causation.  131 
Explorative sub-group analyses were conducted by sex, age at blood draw applying 132 
interaction analyses, as well as by anatomical sub-site. 133 
All statistical analyses were performed with SAS version 9.4 (SAS Institute).  134 
Results 135 
Study characteristics and risk factors for SGG positivity 136 
There were no significant differences between cases and controls in any of the baseline 137 
characteristics (Table 2).  138 
The comparison of SGG positive versus negative control subjects did not identify any major 139 
determinants of SGG positivity (Supplementary table S2).  140 
Association of antibody responses to SGG with CRC risk 141 
The risk of developing CRC was significantly increased with positivity to any of the eleven 142 
SGG proteins (OR: 1.36, 95% CI: 1.04-1.77), and also positivity to individual SGG proteins 143 
Gallo0272 (OR: 1.59, 95% CI: 1.06-2.40), Gallo0748 (OR: 1.49, 95% CI: 1.02-2.16) and 144 
Gallo2178 (OR: 3.01, 95% CI: 1.49-6.08) (Table 3). Positivity for two or more proteins of the 145 
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previously identified 6-marker panel (Gallo0272, Gallo0748, Gallo1675, Gallo2018, 146 
Gallo2178 and Gallo2179)16 was also significantly associated with increased CRC risk (OR: 147 
2.17, 95% CI: 1.44-3.27) with 9% positive controls compared to 17% positive cases.  148 
To assess the potential impact of reverse causation, we performed a sensitivity analysis 149 
excluding those cases diagnosed within 2 years after blood draw and their respective controls 150 
(Table 3). The association for positivity to any of the eleven SGG proteins (OR: 1.38, 95% 151 
CI: 1.02-1.87) as well as positivity to two or more proteins of the 6-marker panel (OR: 2.07, 152 
95% CI: 1.29-3.31) with CRC risk was generally unaltered. Positivity to individual proteins 153 
Gallo0272 (OR: 1.87, 95% CI: 1.15-3.05) and Gallo2178 (OR: 3.28, 95% CI: 1.25-8.57) 154 
retained statistical significance while Gallo0748 lost significance but with little change in the 155 
magnitude of the risk estimate (OR: 1.40, 95% CI: 0.90-2.18).  156 
Explorative subgroup analyses 157 
Positivity for two or more proteins of the 6-marker panel was associated with only a minor 158 
fraction of CRC cases (17%). We assessed whether particular subgroups showed different risk 159 
associations for CRC. Analyses stratified by age at blood draw and sex did not reveal any 160 
statistically significant difference between the subgroups. 161 
Separate analyses by colon or rectal sub-site showed different associations (Fig 2). Positivity 162 
to two or more proteins of the 6-marker panel was associated with a 10-fold increased risk of 163 
rectal cancer (95% CI: 1.05-95.78) and a much lower, but also statistically significant, near 164 
two-fold higher risk for colon cancer (OR: 1.96, 95% CI: 1.28-3.00). However, it is important 165 
to note that the number of rectal cancers was small (n=53) resulting in wide confidence 166 
intervals and imprecision of the risk estimate. 167 
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Discussion 168 
In this CRC case-control study nested within the prospective multinational EPIC cohort we 169 
found that antibody responses to SGG proteins, in particular to two or more proteins 170 
seropositive among a 6-marker panel (Gallo0272, Gallo0748, Gallo1675, Gallo2018, 171 
Gallo2178 and Gallo2179) were significantly associated with risk of developing CRC.  172 
These findings replicate and expand previous findings from two case-control studies with 173 
CRC cases from Spain (multicenter case-control study (MCC Spain))14 and an independent 174 
German study16. In MCC Spain, an association of prevalent CRC with antibody responses to 175 
SGG protein Gallo2178 alone and Gallo2178 in combination with Gallo2179 was found14. In 176 
the German case-control study, the SGG multiplex serology panel was extended to eleven 177 
SGG proteins. Positivity to any of these proteins was associated with prevalent CRC. 178 
Seropositivity for at least two proteins from a 6-marker panel subset (Gallo0272, Gallo0748, 179 
Gallo1675, Gallo2018, Gallo2178 and Gallo2179) was more specifically associated with CRC 180 
(19% SGG positives) compared to controls (11% of SGG-positives)16.  181 
It is currently unknown whether SGG infects colon tissue before or after initiation of tumor 182 
development. However, it is hypothesized that the commensal SGG enters the bloodstream 183 
through a leaky epithelium, arising due to various environmental exposures, or along the 184 
processes of CRC development4. This hypothesis is supported by observations showing the 185 
presence of SGG already in early colorectal lesions, including polyps and adenoma11, 12, 16, 19. 186 
Here, we offer the first prospective observational evidence to support early involvement of 187 
SGG in colon carcinogenesis by showing that antibody responses to SGG were more 188 
frequently present in subjects who later developed CRC even more than two years after blood 189 
draw than those who remained disease-free during the same time-frame. The natural history 190 
of CRC is characterized by the progressive development of neoplasia of the colon mucosa and 191 
can take up to 10-15 years from an initial polyp to tumor diagnosis. Therefore, it is likely that 192 
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a number of individuals in this study, who developed CRC, already had a precancerous lesion 193 
at the time of recruitment into the cohort, but were undiagnosed and likely asymptomatic.  194 
Although we have no data on CRC screening to estimate the numbers with existing polyps, it 195 
is likely to be comparable to other European population studies, such as for Germany where 196 
the detection rate of non-advanced and advanced adenoma was 22.3% and 9.0%, respectively, 197 
among males and 14.9% and 5.2%, respectively, among females above age 55 years20. As 198 
only a minority of adenomas progress to cancer, a similar proportion of the controls would 199 
also be expected to have some form of colorectal adenoma at blood draw that had not 200 
progressed to malignant disease by the end of follow-up. Thus, the finding that antibody 201 
responses to SGG appear prior to cancer diagnosis raises the question whether SGG infection 202 
is a potential etiological factor in the transition of an adenoma to malignant disease and 203 
whether its detection could help stratify the risk for tumor progression from a precancerous 204 
lesion. However, we were unable to directly address this question within the limitations of our 205 
study. Studies by Abdulamir et al. found pro-inflammatory cytokine profiles in human CRC 206 
tissue positive for SGG DNA and support the hypothesis of an involvement of SGG in tumor 207 
progression11, 21. A recent study comprehensively showed that SGG promotes proliferation of 208 
colon cancer cells in vitro and tumor development in a mouse model overall supporting a role 209 
of SGG in colonic tumorigenesis22. Our observations will hopefully stimulate further 210 
epidemiological studies with CRC screening data and mechanistic investigations of the 211 
potential SGG induced transformation of benign polyps to more advanced disease states.  212 
The antigens selected for SGG multiplex serology include proteins predicted to be present at 213 
the cell wall of the bacterium or to be secreted23, 24. Pilus proteins Gallo2178 and Gallo2179, 214 
both included in the 6-marker panel, were previously shown to be potential virulence factors 215 
in endocarditis and for infection of colon tumor tissue by mediating attachment to collagen in 216 
tissue10, 25. Functions of the other proteins had been so far only predicted by sequence 217 
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comparison to proteins of other bacteria and include enzymatic (Gallo0112A/B, Gallo0748, 218 
Gallo0933, Gallo2018) as well as adhesion functions (Gallo0272, Gallo0577, Gallo1570). 219 
The function of Gallo1675 is unknown26. Future studies should focus on this 6-marker panel 220 
as it is a stronger marker for CRC risk than being positive to any of the eleven proteins 221 
included in the multiplex serology (OR: 2.17 vs OR: 1.36, respectively). 222 
Stratification by age and sex did not reveal statistically significant differences. However, the 223 
small sub-group sample sizes may have limited the analysis. Secondary sub-group analysis by 224 
anatomical sub-site suggested a stronger cancer risk association for the rectum versus the 225 
colon with SGG antibody responses. This observation is highly interesting and warrants 226 
further investigation, but is limited due to small number of rectal cancer cases (n=53) 227 
included in the present analysis. The disparity between the number of colon and rectal cancer 228 
cases analyzed in this study are due to limited availability of biological samples for the 229 
required laboratory analyses in this sub-set of EPIC CRC cases.  230 
Key advantages of this study are its prospective setting, multi-center design and the use of a 231 
detailed, validated biomarker approach to assess SGG exposures. A main limitation is the 232 
small sample size, being based on a subset of CRC cases in the EPIC cohort with available 233 
biological samples for the required SGG biomarker analyses. Furthermore, the SGG 234 
exposures assessed here reflect levels at recruitment into the cohort upon blood collection and 235 
so may not pertain to longer term exposures. An additional potential limitation applicable to 236 
all observational studies is the possibility for residual or uncontrolled confounding. Although, 237 
the EPIC data have been very well measured and validated, the possibility of residual 238 
confounding cannot ever be wholly discounted. Uncontrolled confounding is unlikely because 239 
the multivariate adjusted model presented here addressed a large number of potentially 240 
important confounding variables. Nevertheless, in the absence of further confirmation of these 241 
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findings from a larger series of CRC cases from EPIC or from other prospective cohorts, 242 
caution in the interpretation of the findings is necessary.  243 
In conclusion, this study provides the first exploration in a prospective setting of the 244 
association between SGG infection and risk of CRC development. Our observations indicate a 245 
positive association of antibody responses to SGG proteins with CRC risk, taking into account 246 
other important confounding factors. SGG infection, possibly acquired through lifestyle 247 
exposures leading to colonic epithelial barrier dysfunction, may be an important etiological 248 
component of CRC development. Thus, antibody responses to SGG proteins may be 249 
indicative for individuals at increased risk for developing CRC.  250 
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Supplementary Table S1: Antibody responses to SGG proteins and protein combinations in 
relation to CRC risk in a nested case-control study within EPIC 
 Positive n (%) Unadjusted model1 Adjusted model 2 
 Controls Cases    
 n=485 n=485 OR 95% CI OR 95% CI 
Gallo0112A 33 (7) 37 (8) 1.14 0.69-1.90 1.09 0.64-1.84 
Gallo0112B 28 (6) 26 (5) 0.93 0.54-1.60 0.96 0.55-1.67 
Gallo0272 47 (10) 67 (14) 1.49 1.00-2.21 1.59 1.06-2.40 
Gallo0577 47 (10) 49 (10) 1.05 0.69-1.59 1.03 0.67-1.59 
Gallo0748 50 (10) 74 (15) 1.51 1.05-2.18 1.49 1.02-2.16 
Gallo0933 49 (10) 44 (9) 0.89 0.58-1.36 0.92 0.59-1.43 
Gallo1570 47 (10) 52 (11) 1.13 0.73-1.74 1.13 0.72-1.76 
Gallo1675 48 (10) 51 (11) 1.07 0.70-1.63 1.08 0.70-1.67 
Gallo2018 47 (10) 54 (11) 1.16 0.77-1.74 1.24 0.81-1.89 
Gallo2178 12 (2) 31 (6) 2.58 1.33-5.03 3.01 1.49-6.08 
Gallo2179 47 (10) 64 (13) 1.43 0.95-2.14 1.48 0.97-2.24 
Any SGG protein 273 (56) 306 (63) 1.32 1.02-1.71 1.36 1.04-1.77 
≥ 2 of 6-marker panel3 45 (9) 83 (17) 2.03 1.37-3.01 2.17 1.44-3.27 
1Conditional logistic regression model conditioned on the matching factors; 2 Model 1 with further 
adjustment for BMI, highest level of education attainment, smoking status and alcohol intake at 
baseline as categorical variables, missings in the variables considered as individual 
category; 3Gallo0272, Gallo0748, Gallo1675, Gallo2018, Gallo2178, Gallo2179 
  
Supplementary Table S2: Comparison of SGG negative and positive individuals for 
demographic and other risk factors among controls. 
  Any S. gallolyticus protein ≥2 of 6-marker panel2 
  
neg 
(n=212) 
pos 
(n=273) 
p-
value1 
neg 
(n=440) 
pos 
 (n=45) 
p-
value1 
Sex female 103 (49) 144 (53)  225 (51) 22 (49)  
male 109 (51) 129 (47) 0.363 215 (49) 23 (51) 0.774 
Age at blood 
draw, years 
37-55 44 (21) 76 (28)  106 (24) 14 (31)  
56-60 55 (26) 69 (25)  113 (26) 11 (24)  
61-77 113 (53) 128 (47) 0.180 221 (50) 20 (44) 0.573 
mean (range) 60 (39-77) 59 (37-75)  60 (37-77) 59 (37-74)  
Country France 4 (2) 7 (3)  9 (2) 2 (4)  
Italy 47 (22) 54 (20)  95 (22) 6 (13)  
Spain 37 (17) 45 (16)  75 (17) 7 (16)  
 United Kingdom 60 (28) 74 (27)  119 (27) 15 (33)  
 The Netherlands 29 (14) 41 (59)  61 (14) 9 (20)  
 Greece 3 (1) 8 (3)  11 (3) 0 (0)  
 Germany 32 (15) 55 (58) 0.907 70 (16) 6 (13) 0.497 
Education ≤primary school 92 (45) 120 (46)  196 (46) 16 (39)  
technical/professional  54 (26) 61 (23)  103 (24) 12 (29)  
≥secondary school 60 (29) 82 (31) 0.736 129 (30) 13 (32) 0.663 
 missing 6 10  12 4  
BMI <25 76 (36) 91 (33)  151 (34) 16 (36)  
25-29.9 95 (45) 143 (52)  218 (50) 20 (44)  
≥30 41 (19) 39 (14) 0.177 71 (16) 9 (20) 0.739 
Smoking 
status 
never 94 (45) 140 (51)  212 (48) 22 (49)  
former 73 (35) 81 (30)  136 (31) 18 (40)  
 current 44 (21) 51 (19) 0.316 90 (21) 5 (11) 0.238 
missing 1 1  2 0  
Alcohol intake 
at baseline 
(g/day) 
<6 100 (47) 129 (47)  209 (48) 20 (44)  
6-20 54 (25) 73 (27)  118 (27) 9 (20)  
>20 58 (27) 71 (26) 0.925 113 (26) 16 (36) 0.316 
1Pearson’s Chi-Square-test; 2Gallo0272, Gallo0748, Gallo1675, Gallo2018, Gallo2178 and Gallo2179 
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Tables: 1 
Table 1: Antigens included in SGG (strain UCN34) multiplex serology and antigen 2 
specific cut-offs. 3 
Name Putative function 
Antigen specific 
cut-off (MFI) 
Gallo0112A Fructan hydrolase N-terminus 30 
Gallo0112B Fructan hydrolase C-terminus 30 
Gallo0272* Glucan binding protein C domain 192 
Gallo0577 Cell-wall protein with CnaB domain 185 
Gallo0748* Cell-envelope proteinase A 96 
Gallo0933 Tannase 175 
Gallo1570 Pil2 pilus subunit 185 
Gallo1675* Cell wall protein of unknown function 36 
Gallo2018* Putative cell wall protein involved in bacteriocin synthesis 95 
Gallo2178* Pil1 pilus subunit (major pilin) 30 
Gallo2179* Pil1 pilus subunit (collagen-binding domain) 118 
* antigens included in 6-marker panel 
 4 
  5 
Formatted Table
Formatted: English (U.S.)
Formatted: Left
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Table 2: Baseline characteristics of the CRC case-control study nested within EPIC 6 
  
Controls 
(n=485) 
Cases 
(n=485) 
  n (%) n (%) 
Sex female 247 (51) 247 (51) 
male 238 (49) 238 (49) 
Age at blood draw, 
years 
37-55 120 (25) 121 (25) 
56-60 124 (25) 122 (25) 
 61-77 241 (50) 242 (50) 
 Mean (range) 60 (37-77) 59 (37-77) 
Country France 11 (2) 11 (2) 
Italy 101 (21) 101 (21) 
Spain 82 (17) 82 (17) 
United Kingdom 134 (28) 134 (28) 
 The Netherlands 70 (14) 70 (14) 
 Greece 11 (2) 11 (2) 
 Germany 76 (16) 76 (16) 
Education ≤primary school 212 (45) 215 (46) 
Technical/professional 115 (25) 95 (21) 
>=secondary school 142 (30) 153 (33) 
 missing 16 22 
BMI <25 167 (34) 160 (33) 
25-29.9 238 (49) 220 (45) 
≥30 80 (16) 105 (22) 
Smoking status never 234 (48) 202 (42) 
 former 154 (32) 183 (38) 
 current 95 (20) 96 (20) 
missing 2 4 
Alcohol intake at 
baseline (g/day) 
<6 229 (47) 213 (44) 
6-20 127 (26) 127 (26) 
 >20 129 (27) 144 (30) 
 missing 0 1 
  7 
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Table 2: Comparison of SGG negative and positive individuals for demographic and 8 
other risk factors among controls. 9 
  Any S. gallolyticus protein ≥2 of 6-marker panel2 
  
neg 
(n=212) 
pos 
(n=273) 
p-
value1 
neg 
(n=440) 
pos 
 (n=45) 
p-
value1 
Sex female 103 (49) 144 (53)  225 (51) 22 (49)  
male 109 (51) 129 (47) 0.363 215 (49) 23 (51) 0.774 
Age at blood 
draw, years 
37-55 44 (21) 76 (28)  106 (24) 14 (31)  
56-60 55 (26) 69 (25)  113 (26) 11 (24)  
61-77 113 (53) 128 (47) 0.180 221 (50) 20 (44) 0.573 
mean (range) 60 (39-77) 59 (37-75)  60 (37-77) 59 (37-74)  
Country France 4 (2) 7 (3)  9 (2) 2 (4)  
Italy 47 (22) 54 (20)  95 (22) 6 (13)  
Spain 37 (17) 45 (16)  75 (17) 7 (16)  
 United Kingdom 60 (28) 74 (27)  119 (27) 15 (33)  
 The Netherlands 29 (14) 41 (59)  61 (14) 9 (20)  
 Greece 3 (1) 8 (3)  11 (3) 0 (0)  
 Germany 32 (15) 55 (58) 0.907 70 (16) 6 (13) 0.497 
Education ≤primary school 92 (45) 120 (46)  196 (46) 16 (39)  
technical/professional  54 (26) 61 (23)  103 (24) 12 (29)  
≥secondary school 60 (29) 82 (31) 0.736 129 (30) 13 (32) 0.663 
 missing 6 10  12 4  
BMI <25 76 (36) 91 (33)  151 (34) 16 (36)  
25-29.9 95 (45) 143 (52)  218 (50) 20 (44)  
≥30 41 (19) 39 (14) 0.177 71 (16) 9 (20) 0.739 
Smoking 
status 
never 94 (45) 140 (51)  212 (48) 22 (49)  
former 73 (35) 81 (30)  136 (31) 18 (40)  
 current 44 (21) 51 (19) 0.316 90 (21) 5 (11) 0.238 
missing 1 1  2 0  
Alcohol intake 
at baseline 
(g/day) 
<6 100 (47) 129 (47)  209 (48) 20 (44)  
6-20 54 (25) 73 (27)  118 (27) 9 (20)  
>20 58 (27) 71 (26) 0.925 113 (26) 16 (36) 0.316 
1Pearson’s Chi-Square-test; 2Gallo0272, Gallo0748, Gallo1675, Gallo2018, Gallo2178 and Gallo2179 
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Table 43: Antibody responses to SGG proteins in relation to CRC incidence in a nested case-control study within EPIC 10 
 All Diagnosed more than 2 years after blood draw 
 Positive n (%)   Positive n (%)   
 Controls Cases  
 Controls Cases    
 n=485 n=485 OR1 95% CI  n=355 n=355 OR1 95% CI  
Gallo0112A 33 (7) 37 (8) 1.09 0.64-1.84  22 (6) 23 (6) 1.08 0.55-2.11  
Gallo0112B 28 (6) 26 (5) 0.96 0.55-1.67  15 (4) 16 (5) 1.13 0.55-2.32  
Gallo0272 47 (10) 67 (14) 1.59 1.06-2.40  32 (9) 51 (14) 1.87 1.15-3.05  
Gallo0577 47 (10) 49 (10) 1.03 0.67-1.59  34 (10) 36 (10) 1.05 0.64-1.72  
Gallo0748 50 (10) 74 (15) 1.49 1.02-2.16  37 (10) 51 (14) 1.40 0.90-2.18  
Gallo0933 49 (10) 44 (9) 0.92 0.59-1.43  37 (10) 38 (11) 1.05 0.64-1.73  
Gallo1570 47 (10) 52 (11) 1.13 0.72-1.76  36 (10) 41 (12) 1.19 0.72-1.96  
Gallo1675 48 (10) 51 (11) 1.08 0.70-1.67  38 (11) 39 (11) 1.09 0.67-1.76  
Gallo2018 47 (10) 54 (11) 1.24 0.81-1.89  38 (11) 43 (12) 1.22 0.77-1.95  
Gallo2178 12 (2) 31 (6) 3.01 1.49-6.08  7 (2) 17 (5) 3.28 1.25-8.57  
Gallo2179 47 (10) 64 (13) 1.48 0.97-2.24  34 (10) 44 (12) 1.47 0.90-2.40  
Any SGG protein 273 (56) 306 (63) 1.36 1.04-1.77  201 (57) 224 (63) 1.38 1.02-1.87  
≥2 of 6-marker panel2 45 (9) 83 (17) 2.17 1.44-3.27  36 (10) 60 (17) 2.07 1.29-3.31  
1Conditional logistic regression model with multivariable adjustment  for BMI, education, smoking and alcohol intake at baseline; 2Gallo0272, 
Gallo0748, Gallo1675, Gallo2018, Gallo2178, Gallo2179 
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